Blueprint Medicines Corporation (LON:0HOJ)
129.35
-0.04 (-0.03%)
Inactive · Last trade price on Jul 17, 2025
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $149.41M USD in the quarter ending March 31, 2025, with 55.45% growth. This brings the company's revenue in the last twelve months to $562.12M, up 99.19% year-over-year. In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth.
Revenue (ttm)
$562.12M
Revenue Growth
+99.19%
P/S Ratio
14.26
Revenue / Employee
$866.13K
Employees
649
Market Cap
6.21B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 508.82M | 259.44M | 104.04% |
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBlueprint Medicines News
- 3 days ago - Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction - Business Wire
- 22 days ago - Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction - Business Wire
- 2 months ago - $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC) - GlobeNewsWire
- 2 months ago - What's Driving the Market Sentiment Around Blueprint Medicines? - Benzinga
- 3 months ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 3 months ago - Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
- 3 months ago - HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC) - Benzinga
- 3 months ago - HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC) - GlobeNewsWire